An interventional study of 5-HT3 receptor antagonist (e.g., ondansetron) and Acupoint application in Lung Cancer (Diagnosis)Chemotherapy-Induced Nausea and Vomiting, sponsored by Xiu Huang. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Xiu Huang · Not applicable, Interventional, and Supportive care
This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.
Adults with pathologically confirmed lung cancer who are scheduled to receive first-line platinum-based chemotherapy are eligible. After providing written informed consent, participants are randomized 1:1 to receive either acupoint application using a herbal plaster applied to selected acupoints plus standard 5-HT3 receptor antagonist prophylaxis, or 5-HT3 receptor antagonist prophylaxis alone. Nausea and vomiting episodes are recorded by participants using patient diaries, and quality of life is assessed with the Functional Living Index-Emesis questionnaire.
Exclusion Criteria:
Participants receive herbal acupoint plaster applied to selected acupoints plus standard 5-HT3 receptor antagonist prophylaxis before and during one cycle of platinum-based chemotherapy.
Drug: 5-HT3 receptor antagonist (e.g., ondansetron) · Other: Acupoint application
Participants receive standard 5-HT3 receptor antagonist prophylaxis alone before and during one cycle of platinum-based chemotherapy.
Drug: 5-HT3 receptor antagonist (e.g., ondansetron)
Standard antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.
Herbal plaster applied to selected acupoints to alleviate chemotherapy-induced nausea and vomiting.
Complete response rate of delayed-phase CINV (24-120 h)
Complete response is defined as no emetic episodes and no rescue antiemetic use during 24 to 120 hours after the first cycle of platinum-based chemotherapy. The outcome will be compared between the acupoint application plus 5-HT3 receptor antagonist group and the 5-HT3 receptor antagonist alone group.
Time frame: 24 to 120 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
Complete response rate of acute-phase CINV (0-24 h)
Complete response is defined as no emetic episodes and no rescue antiemetic use during 0 to 24 hours after the first cycle of platinum-based chemotherapy.
Time frame: 0 to 24 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
MAT nausea score
Nausea severity measured by the Morrow Assessment of Nausea and Emesis (MAT) questionnaire after the first cycle of platinum-based chemotherapy.
Time frame: During the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
FLIE quality-of-life score
Quality of life assessed by the Functional Living Index-Emesis (FLIE) questionnaire after the first cycle of platinum-based chemotherapy.
Time frame: During the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
Plan to share: Yes — IPD Sharing Plan: Individual participant data that underlie the results reported in this article will be shared after de-identification. Data will be available beginning 3 months and ending 5 years following article publication. Researchers who provide a methodologically sound proposal may request access to the data through the corresponding author. Proposals will be reviewed by the study team to ensure they comply with Chinese data privacy regulations and the informed consent signed by participants.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.